P rimary progressive aphasia (PPA) is a clinical syndrome characterized by progressive loss of language function in the setting of focal degeneration of the dominanthemisphere language network. 1 Although first described in the late 19th century by Pick and Dejerine and Serieux, the notion of isolated, progressive aphasia in the context of a neurodegenerative condition only came to broader medical/ scientific attention in 1982 with Dr Mesulam's seminal observations. 2 Since then, the nosology of PPA has been a field of intense investigation. The first official set of criteria for PPA defined 2 variants-progressive nonfluent aphasia, and semantic aphasia and associative agnosia 3 -which were included under the rubric of frontotemporolobar degeneration (FTLD). As a consequence, amyloid-β (Aβ) pathology (a neuropathological hallmark of Alzheimer disease [AD]) observed at autopsy in patients with PPA [4] [5] [6] was initially considered a comorbid, age-related process. [7] [8] [9] In 2004, cluster analyses of clinical and anatomical data brought Gorno-Tempini and colleagues to define a third (logopenic) variant of PPA (lvPPA), which was predicted to be primarily due to AD. 10 The high prevalence of Aβ positivity in lvPPA was confirmed using molecular imaging, 11 contributing to its label as the "language variant of AD." However, other studies showed high prevalence of AD pathology at autopsy in progressive nonfluent aphasia and, to a lesser extent, in semantic dementia. [12] [13] [14] [15] [16] [17] Inconsistencies between the newly described variant and existing PPA criteria-for instance the overlap between the 1998 Neary criteria for progressive nonfluent aphasia 3 and the initial descriptions of logopenic aphasia 10 -became a growing source of confusion for clinicians and researchers.
To improve uniformity of case reporting and reliability of research results, a comprehensive set of consensus criteria for PPA was published in 2011. 18 Based on specific language profiles, 3 distinct variants were proposed: a nonfluent variant (nfvPPA), characterized by effortful speech output, agrammatism, and apraxia of speech, with relative sparing of single-word comprehension; a semantic variant (svPPA), distinguished by loss of word and object meaning, with fluent and grammatically correct speech; and lvPPA, defined by the co-occurrence of word-finding difficulties and impaired sentence repetition. Based on these updated criteria, clinicopathological studies have shown that AD pathology often underlies lvPPA, whereas nfvPPA and svPPA are typically caused by FTLD pathology. [19] [20] [21] [22] [23] [24] [25] However, despite the application of international consensus clinical criteria, the prevalence of Aβ pathology-either measured at autopsy [19] [20] [21] [22] [23] [24] [25] [26] or using in vivo biomarkers such as cerebrospinal fluid (CSF) analysis or positron emission tomography (PET) [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] -remained highly variable in single-center studies of PPA variants: 57 to 100% in lvPPA, 0 to 46% in nfvPPA, and 0 to 33% in svPPA. Given an estimated prevalence of 3.0/100,000 inhabitants for PPA, 33 a multicenter approach is essential to overcome statistical power issues. We therefore performed an individual patient meta-analysis including 1,251 PPA patients from 36 dementia centers. The primary objective was to provide prevalence estimates of Aβ pathology (determined at autopsy, CSF, and/or PET) for each PPA variant. In secondary analyses, we evaluated relationships between Aβ positivity and the main risk factors for Aβ deposition, notably age and presence of an apolipoprotein E (ApoE) ε4 allele. Furthermore, in a subset of patients with autopsy data available, we assessed the prevalence of neuropathological substrates in the different PPA variants.
Patients and Methods

Participating Centers
We searched the MEDLINE and Web of Science databases for biomarker (i.e., PET and/or CSF) or autopsy studies in PPA patients. The search terms were primary progressive aphasia or PPA combined with biomarkers, pathology, autopsy, neuropathology, cerebrospinal fluid, CSF, PET, PiB, Pittsburgh, florbetapir, AV-45, florbetaben, flutemetamol, amyloid, abeta, frontotemporal, and Alzheimer's disease. A total of 1,012 titles and abstracts were reviewed, resulting in 37 unique cohorts for which we contacted the study corresponding author to obtain primary data. In addition, we contacted principal investigators of dementia centers known to be involved in PPA/frontotemporal dementia research who had not (yet) publish a paper on the specific issue of Aβ pathology in PPA. In total, we asked 42 study contact persons to provide participant-level data on Aβ status, age, sex, education, handedness, ApoE ε4 status, Mini-Mental State Examination (MMSE) score, and Clinical Dementia Rating scale score. Six centers declined or did not respond, leaving participant-level data from 36 cohorts for analysis (Supplementary Table 1 ). We requested contributors to send both published and unpublished data. Informed consent was obtained from all patients or their assigned surrogate decision makers, and the institutional review boards for human research of the participating centers approved all studies.
Data Collection and Operationalization
Information on study procedures, extracted from the publication or provided by the study contact person, was used to create a common set of variables.
Patients
Patients had to fulfil core criteria for PPA (i.e., language impairment being the earliest and most prominent clinical feature and the principal cause of impaired activities of daily living at least during the first 2 years after disease onset). 8, 18 Patients were classified by contributing centers according to the PPA consensus criteria 18 ), cerebrovascular disease, argyrophilic grain disease, prions, and FTLD-fused in sarcoma (FUS). Some patients were analyzed prior to the discovery of TDP subtypes and were therefore coded TDP-unspecified. Aβ pathology was considered "comorbid" when combined with another full-blown pathology (FTLD TDP, primary tauopathy) in the absence of semiquantitative neuritic senile plaque density (CERAD score) and neurofibrillary tangle severity/distribution (Braak stage) adding up to a "high" or "moderate" likelihood of AD.
Clinical Measures and Genetic Testing
The MMSE score (measure of global cognition) was available for 945 patients with PPA (76%). Information on ApoE genotype was available for 487 patients (39%). None of the participating centers' cohorts was enriched for positive ApoE4 status. Age and gender were available for 1,167 (93%) and 1,203 (96%) patients, respectively.
Statistical Analyses
We conducted a meta-analysis with individual participant data. Baseline characteristics were compared using analysis of variance, Fisher exact test, and Pearson chi-squared test where appropriate. Similar to previous meta-analyses, 36, 44 generalized estimating equations (GEE; using SPSS v23.0; IBM, Armonk, NY) models were used to estimate probabilities for Aβ positivity. GEE were used because they allow analysis of binary-correlated data, hence participantlevel data from all cohorts can be modeled while simultaneously accounting for patients within cohorts. A logit link function for binary outcome with an exchangeable correlation structure was assumed to account for withinstudy correlation. Analyses were conducted using the total study population, unless specified otherwise. The main analysis was performed with diagnosis and age as independent variables, adjusted for center effects. Age as entered as a continuous measure centered at the median. We tested 2-way interactions between variables, and these terms were retained in the model if they were significant by the Wald statistical test. ApoE ε4 status was added to the model in secondary analysis of a subset of patients (487/1,251). The slope for each PPA variant according to age was compared to those of probable (mostly amnesticpredominant) AD patients (n = 1,359) and of cognitively normal individuals (n = 2,914), derived from our previous meta-analyses. 36, 44 The degree of heterogeneity in prevalence of amyloid positivity across cohorts was assessed using the I 2 statistic (generated by a random-effects meta-analysis in Stata v14; StataCorp, College Station, TX). An I 2 statistic value > 50% indicates substantial heterogeneity. 45 Significance level was set at 2-sided α = 0.05. Prism version 6.0 (GraphPad, La Jolla, CA) was used for the figures.
Results
A total of 1,251 patients diagnosed with PPA (lvPPA, n = 443; nfvPPA, n = 333; svPPA, n = 401; PPA-M/U, n = 74) and a measure of Aβ pathology (CSF, n = 600; PET, n = 366; or autopsy, n = 378; 93 cases had ≥ 2 modalities) were included from 36 centers ( Table 1) .
Approximately one-third of these cases (425/1,251; 34%) were included in previous publications (see Supplementary  Table 1 ).
Demographic and Clinical Data
The mean age at Aβ measurement was 67.3 ± 8.1 years in the total PPA cohort (see Table 1 ). Patients with svPPA were slightly younger than those with other PPA variants.
Gender was equally distributed across all PPA variants, except in PPA-M/U, in which females were underrepresented (30/74; 40.5%). In all PPA variants, patients were on average highly educated (13.8 ± 4.5 years). Consistent with the general population (non-right-handedness in 8-10% 46 ), 68 of 809 (8.4%) patients were left-handed or ambidextrous. Non-right-handedness was more prevalent in svPPA (10.8%) than in nfvPPA (4.7%; p < 0.05). 
Prevalence of Aβ Positivity by Modality
Prevalence of Aβ positivity within PPA variants was consistent across all 3 modalities (all p > 0.05), except for a higher Aβ positivity in CSF than PET in svPPA (p < 0.05) and a trend toward higher Aβ positivity in PET than autopsy in lvPPA (p = 0.09; Fig 3) . Ninetythree patients had an Aβ pathology measure derived from >1 modality, yielding a 92% concordance rate.
Prevalence of Aβ Positivity according to Age
The estimated prevalence of Aβ positivity across the age span for variants of PPA is presented in Fig 1) . Of note, the slope for lvPPA patients closely resembled that of probable AD patients (n = 1,359), 36 whereas the slopes for svPPA and nfvPPA strongly overlapped with the slope for cognitively normal individuals (n = 2,914; see Fig 1) . 
Discussion
In this multicenter study involving 1,251 patients diagnosed with PPA and a measure of Aβ pathology (CSF, PET, or autopsy), we found that Aβ positivity is more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%). The prevalence of Aβ positivity increased with advancing age in nfvPPA and svPPA (similar to cognitively normal subjects 44 ), but not in lvPPA (in line with probable AD patients 36 ). Furthermore, svPPA and nfvPPA patients carrying a major risk allele for sporadic AD (i.e., ApoE ε4) were more often Aβ + than noncarriers. These results demonstrate the utility of the new classification system 18 to predict underlying pathology of PPA in various clinical settings and suggest that age and ApoE genotype should be considered when interpreting Aβ biomarkers in PPA patients.
In previous individual studies, the prevalence of Aβ pathology detected using in vivo biomarkers or neuropathological examination in patients with distinct variants of PPA differed widely: 57-100% in lvPPA, 0-46% in nfvPPA, and 0-33% in svPPA. [19] [20] [21] [22] [23] [24] [25] [26] 38 This meta-analysis using individual participant data from 36 centers showed that Aβ pathology was present in the vast majority of patients with lvPPA (86%) and in a minority of nfvPPA (20%) and svPPA (16%) cases. Furthermore, autopsy data from 357 PPA patients revealed that AD pathology was the major driving force in lvPPA (76%), whereas FTLD TDP-43 (80%, mostly type C) and FTLD tau (64%) pathology where most prevalent in svPPA and nfvPPA, respectively. These findings are consistent with the notion of selective vulnerability of neural networks to specific proteinopathies, with AD pathology having a tropism toward posterior temporoparietal brain regions, tau pathology toward frontostriatal networks, and TDP-C pathology toward the temporal pole. 19, 47, 48 When these pathologies demonstrate lateralization toward the language-dominant hemisphere, this may result in distinct variants of PPA (lvPPA, nfvPPA, or svPPA, respectively).
The mechanisms underlying lateralization of pathology in PPA remain a mystery. It has been suggested that lefthandedness or developmental learning disabilities (eg, dyslexia) may increase vulnerability of the language-dominant hemisphere to neurodegenerative disorders. 49, 50 In this multicenter study, the proportion of non-right-handedness was similar among PPA variants and consistent with the general population, 46 and there were no data available for learning disabilities. However, handedness data were only available in 25 of 36 centers for 809 of 1,251 patients (65%) and were not evaluated thoroughly using a handedness questionnaire, hence forced right-handedness may be a potential confounder. 51 Genome-wide association studies might shed light on potential contributors to dominant-hemisphere vulnerability in PPA. Similarly, a recent genome-wide association study in posterior cortical atrophy (the "visual variant of AD") revealed associations with genes involved in neurodevelopment of the visual system and retinal degeneration. 52 This study highlights that caution is needed in interpreting the significance of amyloid biomarkers in PPA. Several findings suggest that Aβ pathology may be an agerelated process in svPPA and nfvPPA, comorbid to primary FTLD pathology (i.e., TDP-43 or 3R/4R tau). First, there is a strong increase of Aβ positivity in clinical syndromes mostly associated with non-AD pathologies (i.e., nfvPPA and svPPA) with the presence of 2 main risk factors for sporadic AD (i.e., aging and ApoE ε4). Second, the slopes of increased Aβ positivity according to age in nfvPPA and svPPA (see Fig 2) bear strong resemblance with that of cognitively normal elderly subjects. 44 Finally, our autopsy results showed that more than one-half of Aβ + nfvPPA/svPPA patients exhibit concomitant FTLD pathology, compared to only 6% of Aβ + lvPPA patients (see Fig 3) , which is consistent with several case reports showing that positive Aβ biomarkers do not necessarily indicate that the clinical syndrome is primarily driven by AD pathology. [53] [54] [55] Previous reports have shown that ApoE4 allele was a risk factor for amyloid positivity but not for neuropathological diagnosis of AD in PPA patients. 12, 23, 25 This has potential clinical ramifications, as the increased a priori likelihood of detecting (comorbid) Aβ pathology in older patients and/or ApoE ε4 carriers should be considered when interpreting Aβ biomarkers in patients with PPA. For example, in older patients with a clear clinical profile of nfvPPA or svPPA, a positive amyloid PET should be interpreted with caution, as amyloid PET has lower positive predictive value for AD neuropathology in such patients. 55, 56 Conversely, it is possible that comorbid age-related Aβ pathology may not be an innocent bystander, as recent data suggest that it is associated with worse cognition and greater probability of clinical expression of different dementia syndromes. 36, 57, 58 Apart from the possibility of dual pathologies, there are several other explanations for diverging biomarker results in PPA (eg, Aβ − lvPPA or Aβ + nfvPPA/svPPA). First, the imperfect clinicopathological correlations in PPA may reflect the incomplete tropism of pathogenic proteins for specific brain networks, as proteinopathies sometimes arise in nodes outside their typical "signature" networks. 47, 48 The consensus criteria for PPA captured the vast majority of language profiles of patients in this study. Only 5.9% of PPA could not be classified into 1 of the 3 variants, either because they had unclassifiable (n = 40) or mixed (n = 34) phenotypes. The unclassifiable phenotype primarily included patients with word retrieval and naming deficits who did not fit a diagnosis of lvPPA due to not meeting the core criterion of abnormal repetition. Most patients with a mixed phenotype exhibited core features of multiple PPA variants, for instance, a combination of agrammatism and word comprehension deficits. Likewise, some patients who fit the semantic or agrammatic classification also fulfilled criteria for lvPPA. The prevalence of mixed/unclassifiable phenotypes is consistent with most large cohorts published to date, 19, [22] [23] [24] 33, 38 but lower than others. [64] [65] [66] [67] The heterogeneous pathologies found at autopsy of PPA-M/U subjects suggest that the ambiguities in the current PPA classification cannot be easily resolved through the addition of a fourth clinical variant. Of note, patients with a pure phenotype of primary progressive apraxia of speech 68 were not included in the study if they did not fulfill core criteria for PPA. Many included nfvPPA patients were reported to have predominant apraxia of speech, yet still exhibited language impairments (agrammatism, writing/reading difficulties) consistent with PPA. Finally, MMSE scores were lower in lvPPA (21.0 ± 6.1) and PPA-M/U (21.0 ± 5.5) than in svPPA (23.2 ± 6.1) and nfvPPA (24.0 ± 5.7). This is consistent with previous reports suggesting that patients with PPA due to AD have greater memory, visuospatial, and executive impairment than other PPA variants. [69] [70] [71] [72] Strengths of this study include the large sample size (n = 1,251) from 36 centers, and the inclusion of various measures of Aβ pathology (CSF, PET, and autopsy). Our study also has limitations. First, due to the retrospective nature of the study, there remains an inherent risk for circularity biases, with biomarker results influencing diagnostic classification (or vice versa) due to assumptions regarding clinicopathological correlations. Although we emphasized that coinvestigators provide patients' working diagnosis prior to the biomarker study (i.e., agnostic to Aβ status), we cannot reliably confirm that this was respected at all centers. Likewise, as some scans were performed on a clinical basis-hence readers were not blinded to the clinical diagnosis-we cannot exclude that knowledge of clinical diagnosis has influenced PET visual interpretation in some borderline cases. Prospective studies are needed to mitigate these potential circularity biases. Second, differences in clinical workup across centers-with variable use of neuropsychological assessment, speech/language pathology, and structural and functional imaging-likely had an influence on patients' classification. Uniformly applied, research-level phenotyping of PPA patients would likely have resulted in stronger clinicopathological correlation. 19 ,38 Nevertheless, our study was able to assess the current classification system across a diverse spectrum of clinical settings. Third, acquisition and interpretation methods for PET and CSF were not harmonized across cohorts (eg, different PET tracers, CSF analytical steps, neuropathological procedures). We addressed this using center-or method-specific cutpoints and corrected for center effects. Importantly, I 2 statistics did not reveal significant study-related heterogeneity between centers. Furthermore, post hoc analyses showed no significant differences across modalities. Fourth, when interpreting this study, some sample characteristics should be considered. For example, most patients visited tertiary referral centers and patients were highly educated (13.8 years on average). Finally, because the majority of PPA research focused on the FTLD spectrum, ApoE genotype information was only available in 40% of the sample.
In conclusion, this multicenter study helps to refine our understanding of clinicopathological correlations in PPA. In future studies, further investigations of clinical, structural/functional imaging, and genetic features of PPA are needed to increase our knowledge of PPA pathogenesis. This will improve accuracy of the PPA diagnosis and the identification of the underlying etiology, which will lead to more accurate and efficient participant inclusion in clinical trials with disease-modifying agents tailored to reduce cerebral Aβ, tau, and/or TDP-43 pathology. Furthermore, the field would benefit from a prospective multicenter trial assessing the potential benefit of cholinesterase inhibitors in lvPPA and other Aβ + PPA variants. As with most rare disorders (prevalence = 3.0/100,000), PPA will benefit from tight collaboration between researchers worldwide to obtain sufficient sample size.
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